DNA Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -207.93% compared to Ginkgo Bioworks Holdings, Inc.'s net margin of --. Ginkgo Bioworks Holdings, Inc.'s return on equity of -50.92% beat CEL-SCI Corp.'s return on equity of -266.61%.

Ginkgo Bioworks Holdings, Inc. has a consensus price target of $10.67, signalling upside risk potential of 18.39%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 613.09%. Given that CEL-SCI Corp. has higher upside potential than Ginkgo Bioworks Holdings, Inc., analysts believe CEL-SCI Corp. is more attractive than Ginkgo Bioworks Holdings, Inc..

Ginkgo Bioworks Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Ginkgo Bioworks Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings, Inc. quarterly revenues are $38.8M, which are larger than CEL-SCI Corp. quarterly revenues of --. Ginkgo Bioworks Holdings, Inc.'s net income of -$80.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Ginkgo Bioworks Holdings, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings, Inc. is 2.73x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics, Inc. has a net margin of -207.93% compared to Ginkgo Bioworks Holdings, Inc.'s net margin of 49.46%. Ginkgo Bioworks Holdings, Inc.'s return on equity of -50.92% beat Halozyme Therapeutics, Inc.'s return on equity of 139.43%.

Ginkgo Bioworks Holdings, Inc. has a consensus price target of $10.67, signalling upside risk potential of 18.39%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $76.00 which suggests that it could grow by 17.54%. Given that Ginkgo Bioworks Holdings, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Ginkgo Bioworks Holdings, Inc. is more attractive than Halozyme Therapeutics, Inc..

Ginkgo Bioworks Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.224%.

Ginkgo Bioworks Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings, Inc. quarterly revenues are $38.8M, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $354.3M. Ginkgo Bioworks Holdings, Inc.'s net income of -$80.8M is lower than Halozyme Therapeutics, Inc.'s net income of $175.2M. Notably, Ginkgo Bioworks Holdings, Inc.'s price-to-earnings ratio is -- while Halozyme Therapeutics, Inc.'s PE ratio is 13.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings, Inc. is 2.73x versus 6.53x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -207.93% compared to Ginkgo Bioworks Holdings, Inc.'s net margin of -953.4%. Ginkgo Bioworks Holdings, Inc.'s return on equity of -50.92% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Ginkgo Bioworks Holdings, Inc. has a consensus price target of $10.67, signalling upside risk potential of 18.39%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1141.72%. Given that IGC Pharma, Inc. has higher upside potential than Ginkgo Bioworks Holdings, Inc., analysts believe IGC Pharma, Inc. is more attractive than Ginkgo Bioworks Holdings, Inc..

Ginkgo Bioworks Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Ginkgo Bioworks Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings, Inc. quarterly revenues are $38.8M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Ginkgo Bioworks Holdings, Inc.'s net income of -$80.8M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Ginkgo Bioworks Holdings, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings, Inc. is 2.73x versus 22.66x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -207.93% compared to Ginkgo Bioworks Holdings, Inc.'s net margin of -255.85%. Ginkgo Bioworks Holdings, Inc.'s return on equity of -50.92% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Ginkgo Bioworks Holdings, Inc. has a consensus price target of $10.67, signalling upside risk potential of 18.39%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Ginkgo Bioworks Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Ginkgo Bioworks Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Ginkgo Bioworks Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Ginkgo Bioworks Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Ginkgo Bioworks Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings, Inc. quarterly revenues are $38.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Ginkgo Bioworks Holdings, Inc.'s net income of -$80.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Ginkgo Bioworks Holdings, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings, Inc. is 2.73x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.